Vascular density does not predict future metastatic disease in clinical stage 1 non-seminomatous germ cell tumours of the testis

Histopathology

Volumn 32, Issue 3, 1998, Pages 217-224

  Maher, T M ^a   Lee, A H S ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Pathological neovascularization; Prognosis; Testicular neoplasms

Indexed keywords

ARTICLE; CANCER INVASION; CANCER RECURRENCE; CLINICAL ARTICLE; EARLY CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEOVASCULARIZATION (PATHOLOGY); NON SEMINOMATOUS GERMINOMA; PRIORITY JOURNAL; PROGNOSIS; TESTIS TUMOR;

ADOLESCENT; ADULT; BLOOD VESSELS; GERMINOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; ORCHIECTOMY; PROGNOSIS; RECURRENCE; TERATOMA; TESTICULAR NEOPLASMS; TIME FACTORS;

EID: 0031911834     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1998.00350.x     Document Type: Article

References (27)

1. Freedman LS, Parkinson MC, Jones WG et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 1987: 2; 294-298.
2. Dunphy CH, Ayala AG, Swanson DA, Ro JY, Logothetis C. Clinical stage I nonseminomatous and mixed germ cell tumors of the testis. A clinicopathologic study of 93 patients on a surveillance protocol after orchidectomy alone. Cancer 1988: 62; 1202-1206.
3. Jacobsen GK, Rorth M, Osterlind K et al. Histopathological features in stage I non-seminomatous testicular germ cell tumours correlated to relapse. APMIS 1990: 98; 377-382.
4. Read G, Stenning SP, Cullen MH et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. J. Clin. Oncol. 1992: 10; 1762-1768.
5. Sturgeon JFG, Jewett MAS, Alison RE et al. Surveillance after orchidectomy for patients with clinical stage I non seminomatous testis tumours. J. Clin. Oncol. 1992: 10; 564-568.
6. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Br. J. Urol. 1993: 71; 326-335.
7. Pont J, Albrecht W, Postner G, Sellner F, Angel K, Holtl W. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J. Clin. Oncol. 1996: 14; 441-448.
8. Moul JW, McCarthy WF, Fernandez EB, Sesterhenn IA. Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I non-seminomatous testicular cancer. Cancer Res. 1994: 54; 362-364.
9. Heidenreich A, Sesterhenn IA, Moul JW. Prognostic risk factors in low stage testicular germ cell tumors. Unanswered questions regarding clinically useful prognosticators for extratesticular disease (Editorial). Cancer 1997: 79; 1641-1645.
10. Olivarez D, Ulbright T, DeRiese W et al. Neovascularizatoin in clinical stage A testicular germ cell tumor: prediction of metastatic disease. Cancer Res. 1994: 54; 2800-2802.
11. Albers P, Bierhoff E, Neu D, Fimmers R, Wernert N, Muller SC. MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis. Cancer 1997: 79; 1710-1716.
12. Sesterhenn IA, Weiss RB, Mostofi FK et al. Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study. J. Clin. Oncol. 1942: 10; 69-78.
13. Fox SB, Gatter KC, Marris AL. Tumour angiogenesis. J. Pathol. 1996: 179; 232-237.
14. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo (Letter). Nature 1993: 362; 841-844.
15. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl. J. Med. 1991: 324; 1-8.
16. Weidner N, Folkman J, Pozza F et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 1992: 84; 1875-1887.
17. Horak ER, Leek R, Klenk N et al. Angiogenesis. assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992: 340; 1120-1124.
18. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 1993: 143; 401-409.
19. Mepham BL, Britten KJM. Immunostaining methods for frozen and paraffin sections. In: Jones DB, Wright DH, eds. Lymphoproliferative Diseases. London: Kluwer Academic Publishers, 1990; 187-211.
20. Cattoretti G, Pileri S, Parravicini C et al. Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J. Pathol. 1993: 171; 83-98.
21. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986: 1; 307-310.
22. Fox SB. Tumour angiogenesis and prognosis. Histopathology 1997: 30; 294-301.
23. van de Rijn M, Rouse RV. CD34. A review. Appl. Immunohistochem. 1994: 2; 71-80.
24. Vermeulen PB, Gasparini G, Fox SB et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur. J. Cancer 1996: 32A; 2474-2484.
25. Lee AHS, Happerfield LC, Bobrow LG. Comparison of four endothelial markers for assessing angiogenesis in carcinoma of the breast. J. Cellular Pathol. 1997: 2; 67-73.
26. Klepp O, Olsson AM, Henrikson H et al. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. J. Clin. Oncol. 1990: 8; 509-518.
27. de Jong JS, van Diest PJ, Baak JPA. Heterogeneity and reproducibility of microvessel counts in breast cancer. Lab. Invest. 1995: 73; 922-926.